Tecovirimat for smallpox infections

Drugs of Today

Volumn 46, Issue 2, 2010, Pages 109-117

  Bolken, T C ^a   Hruby, D E ^a  

^a SIGA Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; IMIQUIMOD; IMMUNOGLOBULIN; PLACEBO; PROBENECID; SMALLPOX VACCINE; ST 246; TECOVIRIMAT; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BIOLOGICAL WARFARE; CLINICAL TRIAL; COWPOX VIRUS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; ECZEMA; ECZEMA VACCINATUM; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONKEYPOX VIRUS; NONHUMAN; POXVIRUS; REVIEW; SCALE UP; SMALLPOX; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VACCINIA; VIRUS MUTATION; VIRUS REPLICATION;

EID: 77953553835     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.2.1437244     Document Type: Review

References (44)

1. Alibek, K. The Soviet Union's anti-agricultural biological weapons. Ann N Y Acad Sci 1999, 894: 18-9.
2. Damon, I.K. Orthopoxviruses: Vaccinia (smallpox vaccine), variola (smallpox) monkeypox and cowpox. In: Mandell, G.L., Bennett, J.E., Dolin, R., editors. Mandell, Douglas, Bennets Principles Pract Infect Dis. New York, NY: Churchill Livingstone, 2010, 1923-32.
3. Jackson, R.J., Ramsay, A.J., Christensen, C.D., Beaton, S., Hall, D.F., Ramshaw, I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001, 75(3): 1205-10.
4. Karem, K.L., Reynolds, M., Hughes, C. et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 2007, 14(10): 1318-27.
5. Taub, D.D., Ershler, W.B., Janowski, M. et al. Immunity from smallpox vaccine persists for decades: A longitudinal study. Am J Med 2008, 121(12): 1058-64.
6. Di Giulio, D.B., Eckburg, P.B. Human monkeypox: An emerging zoonosis. Lancet Infect Dis 2004, 4(1): 15-25.
7. Parker, S., Nuara, A., Buller, R.M., Schultz, D.A. Human monkeypox: An emerging zoonotic disease. Future Microbiol 2007, 2: 17-34.
8. World Health Organisation. WHO advisory committee on variola virus research: Report of the tenth meeting. World Health Organization, Geneva, Switzerland: http://www.who.int/en/, 2008.
9. Henderson, D.A. The history of smallpox eradication. Henry E Sigerist Suppl Bull Hist Med 1980(4): 99-114.
10. Cono, J., Casey, C.G., Bell, D.M., Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003, 52(RR-4): 1-28.
11. Fulginiti, V.A., Papier, A., Lane, J.M., Neff, J.M., Henderson, D.A. Smallpox vaccination: A review, part II. Adverse events. Clin Infect Dis 2003, 37(2): 251-71.
12. Centers for Disease Control and Prevention. Emergency Preparedness and Response, http://www.bt.cdc.gov/agent/smallpox/clinicians.asp, accessed 11 February 2010.
13. Jacobs, B.L., Langland, J.O., Kibler, K.V. et al. Vaccinia virus vaccines: Past, present and future. Antiviral Res 2009, 84(1): 1-13.
14. Bavarian Nordic. Pipeline. www.bavarian-nordic.com/pipeline.aspx, accessed 11 February 2010.
15. Grandpre, L.E., Duke-Cohan, J.S., Ewald, B.A. et al. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine 2009, 27(10): 1549-56.
16. Vora, S., Damon, I., Fulginiti, V. et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 46(10): 1555-61.
17. Centers for Disease Control and Progression. Progressive vaccinia in a military smallpox vaccinee. MMWR Morb Mortal Wkly Rep 2009, 58(19): 532-6.
18. De Clercq, E. Acyclic nucleoside phosphonates: Past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge. Biochem Pharmacol 2007, 73(7): 911-22.
19. Snoeck, R., Andrei, G., De Clercq, E. Therapy of poxvirus infections. In: Poxviruses. Mercer, A., Schmidt, A., Weber, O. (Eds.). Basel: Birkhauser Verlag, 2007, 375-96.
20. Davies, E.G., Thrasher, A., Lacey, K., Harper, J. Topical cidofovir for severe molluscum contagiosum. Lancet 1999, 353(9169): 2042.
21. Meadows, K.P., Tyring, S.K., Pavia, A.T., Rallis, T.M. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997, 133(8): 987-90.
22. Zabawski, E.J. Jr, Cockered, C.J. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol 1999, 16(5): 414-5.
23. Yang, G., Pevear, D.C., Davies, M.H. et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 2005, 79(20): 13139-49.
24. Bailey, T.R., Rippin, S.R., Opsitnick, E. et al. N-(3,3a,4,4a,5,5a,6,6a- Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress Inhibitors. J Med Chem 2007, 50(7): 1442-4.
25. Chen, Y., Honeychurch, K.M., Yang, G. et al. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J 2009, 6: 44.
26. Duraffour, S., Snoeck, R., de Vos, R. et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther 2007, 12(8): 1205-16.
27. Duraffour, S., Vigne, S., Vermeire, K. et al. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir Ther 2008, 13(8): 977-90.
28. Smith, S.K., Olson, V.A., Karem, K.L., Jordan, R., Hruby, D.E., Damon, I.K. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother 2009, 53(3): 1007-12.
29. Murray, J.L., Mavrakis, M., McDonald, N.J. et al. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol 2005, 79(18): 11742-51.
30. Grosenbach, D.W., Ulaeto, D.O., Hruby, D.E. Palmitylation of the vaccinia virus 37-kDa major envelope antigen. Identification of a conserved acceptor motif and biological relevance. J Biol Chem 1997, 272(3): 1956-64.
31. Roper, R.L., Moss, B. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J Virol 1999, 73(2): 1108-17.
32. Quenelle, D.C., Buller, R.M., Parker, S., Keith, K.A., Hruby, D.E., Jordan, R., Kern, E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 2007, 51(2): 689-95.
33. Berhanu, A., King, D.S., Mosier, S., Jordan, R., Jones, K.F., Hruby, D.E., Grosenbach, D.W. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother 2009, 53(12): 4999-5009.
34. Nalca, A., Hatkin, J.M., Garza, N.L., Nichols, D.K., Norris, S.W., Hruby, D.E., Jordan, R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 2008, 79(2): 121-7.
35. Sbrana, E., Jordan, R., Hruby, D.E. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 2007, 76(4): 768-73.
36. Huggins, J., Goff, A., Hensley, L. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009, 53(6): 2620-5.
37. Jordan, R., Goff, A., Frimm, A. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 2009, 53(5): 1817-22.
38. Jordan, R., Tien, D., Bolken, T.C. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother 2008, 52(5): 1721-7.
39. Jordan, R., Tyavanagimatt, S.R., Amantana, A. et al. Safety, pharmacokinetics and human dose for ST-246: A novel egress inhibitor being developed for treatment of pathogenic orthopoxvirus infections. 49th Intersci Conf Antimicrob Agents Chemother (Sept 12-15, San Francisco) 2009, Abst A1-593.
40. Phase I trial of an investigational small pox medication (NCT00728689). http://clinicaltrials.gov/ct2/show/NCT00728689, accessed 11 February 2010.
41. Safety, tolerability, pharmacokinetics (PK) of the anti-orthopox drug, ST-246 (246-sofety) (NCT00907803). http://clinicaltrials.gov/ct2/show/ NCT00907803, accessed 11 February 2010.
42. SIGA Technologies. ST-246 used to treat complications from exposure to recombinant vaccinia virus, http://investor.siga.com/releasedetail.cfm? ReleaseID=409235, date accessed 11 February 2010.
43. Grosenbach, D.W., Jordan, R., King, D.S. et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008, 26(7): 933-46.
44. Wei, H., Huang, D., Fortman, J., Wang, R., Shao, L., Chen, Z.W. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol 2009, 83(2): 1115-25.